Stockscreener 앱 받기
34.33
2.88%
-1.067
전일 마감가:
$35.40
열려 있는:
$35.62
하루 거래량:
827.74K
Relative Volume:
0.52
시가총액:
$5.09B
수익:
$813.46M
순이익/손실:
$-365.74M
주가수익비율:
-11.96
EPS:
-2.87
순현금흐름:
$-375.18M
1주 성능:
-7.66%
1개월 성능:
-11.85%
6개월 성능:
-8.00%
1년 성능:
-29.89%
1일 변동 폭
$34.29
$35.65
1주일 범위
$33.33
$37.29
52주 변동 폭
$33.33
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IONS | 34.30 | 5.09B | 813.46M | -365.74M | -375.18M | -2.87 |
| VRTX | 449.25 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.78 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.73 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Beta-thalassemia Market is Predicted to Exhibit Remarkable - openPR
Transthyretin Amyloidosis Treatment Market Top PlayersIonis - openPR
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angel - GuruFocus.com
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Ionis reaches agreement on phase 3 trial design for Angelman candidate - MSN
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now - MSN
Familial Chylomicronemia Syndrome Market Expected - openPR
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks - Yahoo Finance
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Large Increase in Short Interest - MarketBeat
RSI Alert: Ionis Pharmaceuticals (IONS) Now Oversold - Nasdaq
BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals - GuruFocus.com
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year Low on Insider Selling - MarketBeat
Insider Sale: CEO Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com
Ionis Pharmaceuticals EVP Eric Swayze sells shares worth $45,277 - Investing.com
Ionis Pharmaceuticals director Joseph Loscalzo sells shares for $511,426 - Investing.com
Ionis Pharmaceuticals CEO Brett Monia sells $252,294 in stock - Investing.com
T. Rowe Price Investment Management, Inc. Expands Stake in Ionis Pharmaceuticals Inc - GuruFocus.com
Piper Sandler Issues Pessimistic Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer - cnhinews.com
Baillie Gifford & Co. Sells 220,673 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year - Investing.com
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
StockNews.com Downgrades Ionis Pharmaceuticals (NASDAQ:IONS) to Sell - MarketBeat
What is Leerink Partnrs' Forecast for IONS FY2024 Earnings? - MarketBeat
Wellington Management Group LLP Increases Stake in Ionis Pharmac - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Call Transcript - Insider Monkey
FY2028 EPS Estimates for IONS Reduced by Leerink Partnrs - MarketBeat
ARK Investment Management LLC Buys 23,244 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus - MSN
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Ionis to present at upcoming investor conferences - GuruFocus.com
FDA agrees to review Ionis’ donidalorsen as treatment for HAE - Angioedema News Today
Is there a 2024 Duloxetine recall? FDA flags 7,100+ bottles of generic Cymbalta antidepressants - AOL
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Why Walgreens, CVS and Rite Aid are closing thousands of drug stores across America - AOL
Needham & Company LLC Reaffirms Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - MarketBeat
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - AOL
Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan
Ionis announces design for Phase III trial of Angelman syndrome therapy - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo Finance
Ionis Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights
Ionis Pharmaceuticals Beats on Revenue - The Motley Fool
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings: Revenue Surpa - GuruFocus.com
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - The Motley Fool
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer |
Nov 12 '24 |
Sale |
38.05 |
6,630 |
252,294 |
167,393 |
| LOSCALZO JOSEPH | Director |
Nov 12 '24 |
Sale |
37.86 |
13,508 |
511,426 |
32,251 |
1.80%
0.42%
자본화:
|
볼륨(24시간):